Aplastic Anemia
Conditions
Keywords
Fludarabine, Cyclophosphamide, TBI, severe aplastic anemia,, cord blood transplantation, pediatric
Brief summary
Severe aplastic anemia is a fatal disease and patients without HLA matched siblings need alternative treatment option. Cord blood transplantation (CBT) has become an alternative treatment means in various diseases, but it has not been proved to be good for severe aplastic anemia. Double units CBT is proposed to have better engraftment potential and and we reported successful double units UCBT after engraftment failure with single unit with promising result. To increase the engraftment potential, fludarabine, cyclophosphamide plus TBI conditioning regimen for double units cord blood transplantation was proposed for the patient with severe aplastic anemia without HLA-matched donor.
Interventions
OTHERCyclophosphosphamide, TBI
fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, & -2) (if body weight \< 10 kg or if age \< 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, & -8) total body irradiation (3G on days -1)
Sponsors
The Korean Society of Pediatric Hematology Oncology
Study design
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 21 Years
Healthy volunteers
No
Inclusion criteria
* Diagnosis of severe aplastic anemia defined by any two or three peripheral blood criteria and either marrow criterion. * Peripheral blood * Neutrophils \< 0.5 x 109/l * Platelets \< 20 x 109/l * Corrected reticulocytes \< 1% * Bone marrow * Severe hypocellularity (\< 25%) * Moderate hypocellularity (25-30%) with hematopoietic cells representing \< 30% of residual cells * No prior hematopoietic stem cell transplantation. * Age: no limits. * Performance status: ECOG 0-2. * Patients must be free of significant functional deficits in major organs, but the following eligibility criteria may be modified in individual cases. * Heart: a shortening fraction \> 30%, ejection fraction \> 45%. * Liver: total bilirubin \< 2 × upper limit of normal; ALT \< 3 × upper limit of normal. * Kidney: creatinine \<2 × normal or a creatinine clearance (GFR) \> 60 ml/min/1.73m2. * Patients must lack any active viral infections or active fungal infection. * No appropriate donor * Appropriate cord blood is available: matched at least in 4/6 of A, B, DR loci. * Patients (or one of parents if patients age \< 19) should sign informed consent.
Exclusion criteria
* Pregnant or nursing women. * Malignant or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complications of study therapy. * Psychiatric disorder that would preclude compliance. * Congenital aplastic anemia including Fanconi anemia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the engraftment potential of fludarabine, busulfan plus thymoglobulin conditioning regimen for cord blood transplantation (CBT) in severe aplastic anemia. | From Oct 2008. to Sep 2011 |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate overall and event free survival rate | From Oct 2008. to Sep 2011 |
| To evaluate acute and chronic GVHD | From Oct 2008. to Sep 2011 |
| To evaluate immunologic recovery after CBT | From Oct 2008. to Sep 2011 |
| To evaluate the incidence and severity of toxicity and treatment related mortality | From Oct 2008. to Sep 2011 |
Countries
South Korea
Contacts
Primary ContactHyoung Jin Kang, M.D, Ph.D
Backup ContactJi Won Lee, M.D
Outcome results
None listed